Sage Therapeutics, Inc. Operating Lease Cost
Sage Therapeutics, Inc. reported Operating Lease Cost of $5.97 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-02-11
- Sage Therapeutics, Inc. operating lease, cost for the quarter ending 2019-12-31 was $2.46M.
- Sage Therapeutics, Inc. operating lease, cost for the quarter ending 2019-09-30 was $2.46M.
- Sage Therapeutics, Inc. operating lease, cost for the quarter ending 2019-06-30 was $2.44M.
- Sage Therapeutics, Inc. operating lease, cost for the quarter ending 2019-03-31 was $2.44M.
- Sage Therapeutics, Inc. operating lease, cost for fiscal 2024 was $5.97M, a 11.50% decline from fiscal 2023.
- Sage Therapeutics, Inc. operating lease, cost for fiscal 2023 was $6.75M, a 0.00% change from fiscal 2022.
- Sage Therapeutics, Inc. operating lease, cost for fiscal 2022 was $6.75M, a 22.86% decline from fiscal 2021.
- Sage Therapeutics, Inc. operating lease, cost for fiscal 2021 was $8.75M, a 1.02% decline from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $5.97M 10-K · filed 2025-02-11 | |||
| 2023-12-31 | $6.75M 10-K · filed 2025-02-11 | |||
| 2022-12-31 | $6.75M 10-K · filed 2025-02-11 | |||
| 2021-12-31 | $8.75M 10-K · filed 2024-02-14 | |||
| 2020-12-31 | $8.84M 10-K · filed 2023-02-16 | |||
| 2019-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.92M derived: sum of 2 quarters · filed 2022-02-24 | $7.36M derived: sum of 3 quarters · filed 2022-02-24 | $9.80M 10-K · filed 2022-02-24 |
| 2019-09-30 | $2.46M 10-Q · filed 2019-11-12 | $4.90M derived: sum of 2 quarters · filed 2019-11-12 | $7.34M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.44M 10-Q · filed 2019-08-06 | $4.88M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $2.44M 10-Q · filed 2019-05-02 |